156 related articles for article (PubMed ID: 22799631)
1. Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice.
Kim JH; Kolozsvary A; Jenrow KA; Brown SL
Radiat Res; 2012 Sep; 178(3):202-6. PubMed ID: 22799631
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent inhibition of pan-inflammatory cytokines mitigates radiation-induced skin injury in mice.
Jenrow KA; Brown SL; Kolozsvary AJ; Lapanowski K; Kim JH
Radiat Res; 2014 Sep; 182(3):316-21. PubMed ID: 25098729
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis.
Shu HK; Yoon Y; Hong S; Xu K; Gao H; Hao C; Torres-Gonzalez E; Nayra C; Rojas M; Shim H
PLoS One; 2013; 8(11):e79768. PubMed ID: 24244561
[TBL] [Abstract][Full Text] [Related]
4. The Involvement of SDF-1α/CXCR4 Axis in Radiation-Induced Acute Injury and Fibrosis of Skin.
Cao J; Zhu W; Yu D; Pan L; Zhong L; Xiao Y; Gao Y; Jiao Y; Zhang Q; Ji J; Yang H; Zhang S; Cao J
Radiat Res; 2019 Aug; 192(4):410-421. PubMed ID: 31390312
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of transplanted dermal multipotent stem cells to sites of injury in rats with combined radiation and wound injury by interaction of SDF-1 and CXCR4.
Zong ZW; Cheng TM; Su YP; Ran XZ; Shen Y; Li N; Ai GP; Dong SW; Xu H
Radiat Res; 2008 Oct; 170(4):444-50. PubMed ID: 19024651
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
[TBL] [Abstract][Full Text] [Related]
8. Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers.
De Clercq E
Pharmacol Ther; 2010 Dec; 128(3):509-18. PubMed ID: 20826182
[TBL] [Abstract][Full Text] [Related]
9. Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.
Ludwig A; Saffrich R; Eckstein V; Bruckner T; Wagner W; Ho AD; Wuchter P
Cytotherapy; 2014 Jan; 16(1):111-21. PubMed ID: 24119647
[TBL] [Abstract][Full Text] [Related]
10. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
Lecavalier-Barsoum M; Chaudary N; Han K; Pintilie M; Hill RP; Milosevic M
Br J Cancer; 2019 Jul; 121(3):249-256. PubMed ID: 31239542
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells.
Liu H; Liu H; Deng X; Chen M; Han X; Yan W; Wang N
Wound Repair Regen; 2017 Aug; 25(4):652-664. PubMed ID: 28783870
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.
Wuchter P; Leinweber C; Saffrich R; Hanke M; Eckstein V; Ho AD; Grunze M; Rosenhahn A
Cell Tissue Res; 2014 Feb; 355(2):315-26. PubMed ID: 24337688
[TBL] [Abstract][Full Text] [Related]
16. Short-term injection of antiapoptotic cytokine combinations soon after lethal gamma -irradiation promotes survival.
Hérodin F; Bourin P; Mayol JF; Lataillade JJ; Drouet M
Blood; 2003 Apr; 101(7):2609-16. PubMed ID: 12468435
[TBL] [Abstract][Full Text] [Related]
17. Targeted antagonism of CXCR4 mobilizes progenitor cells under investigation for cardiovascular disease.
Blum A; Childs RW; Smith A; Patibandla S; Zalos G; Samsel L; McCoy JP; Calandra G; Csako G; Cannon RO
Cytotherapy; 2009; 11(8):1016-9. PubMed ID: 19929465
[TBL] [Abstract][Full Text] [Related]
18. A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).
Cooper TM; Sison EAR; Baker SD; Li L; Ahmed A; Trippett T; Gore L; Macy ME; Narendran A; August K; Absalon MJ; Boklan J; Pollard J; Magoon D; Brown PA
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28409853
[TBL] [Abstract][Full Text] [Related]
19. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Agarwal A; Fleischman AG; Petersen CL; MacKenzie R; Luty S; Loriaux M; Druker BJ; Woltjer RL; Deininger MW
Blood; 2012 Sep; 120(13):2658-68. PubMed ID: 22889761
[TBL] [Abstract][Full Text] [Related]
20. IPW-5371 Proves Effective as a Radiation Countermeasure by Mitigating Radiation-Induced Late Effects.
Rabender C; Mezzaroma E; Mauro AG; Mullangi R; Abbate A; Anscher M; Hart B; Mikkelsen R
Radiat Res; 2016 Nov; 186(5):478-488. PubMed ID: 27841740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
